3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Thoracic
1
Head & Neck
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
32
Leukemia, Myeloid, Acute
31
Myelodysplastic Syndromes
29
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia
21
Leukemia, Myelomonocytic, Chronic
18
Lymphoma, Non-Hodgkin
17
Myeloproliferative Disorders
15
Thrombocytopenia
13
Anemia, Aplastic
13
Anemia
12
Hodgkin Disease
11
Hematologic Neoplasms
11
Multiple Myeloma
10
Lymphoma
10
Leukemia, Lymphocytic, Chronic, B-Cell
9
Anemia, Refractory
9
Lymphoma, Mantle-Cell
8
Lymphoma, Follicular
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Fanconi Anemia
7
Congenital Abnormalities
7
Blast Crisis
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Cytopenia
6
Neoplasms
5
Lymphoma, B-Cell, Marginal Zone
5
Burkitt Lymphoma
5
Primary Immunodeficiency Diseases
4
Interventions
eltrombopag
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pathologic Complete Response
×
Classical hematology
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts